(Q33748701)

29 July 2017

1 reference

title

Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy (English)

1 reference

29 July 2017

Sciarra A

1

1 reference

29 July 2017

Casale P

2

1 reference

29 July 2017

Colella D

3

1 reference

29 July 2017

Di Chiro C

4

1 reference

29 July 2017

Di Silverio F

5

1 reference

29 July 2017

publication date

1 August 1999

1 reference

Scandinavian Journal of Urology and Nephrology

29 July 2017

published in

1 reference

29 July 2017

volume

33

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

211-216

1 reference

Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

Phase II studies on prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F003655999750015790

10.1080/003655999750015790

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference